These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 38680684)

  • 1. Assembling the RNA therapeutics toolbox.
    Teng M; Xia ZJ; Lo N; Daud K; He HH
    Med Rev (2021); 2024 Apr; 4(2):110-128. PubMed ID: 38680684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative developments and emerging technologies in RNA therapeutics.
    Halloy F; Biscans A; Bujold KE; Debacker A; Hill AC; Lacroix A; Luige O; Strömberg R; Sundstrom L; Vogel J; Ghidini A
    RNA Biol; 2022; 19(1):313-332. PubMed ID: 35188077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic modified messenger RNA for therapeutic applications.
    Gao M; Zhang Q; Feng XH; Liu J
    Acta Biomater; 2021 Sep; 131():1-15. PubMed ID: 34133982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
    Traber GM; Yu AM
    J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development.
    Lu M; Xing H; Zheng A; Huang Y; Liang XJ
    Acc Chem Res; 2023 Feb; 56(3):224-236. PubMed ID: 36624086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the delivery of RNA therapeutics: from concept to clinical reality.
    Kaczmarek JC; Kowalski PS; Anderson DG
    Genome Med; 2017 Jun; 9(1):60. PubMed ID: 28655327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases.
    Landmesser U; Poller W; Tsimikas S; Most P; Paneni F; Lüscher TF
    Eur Heart J; 2020 Oct; 41(40):3884-3899. PubMed ID: 32350510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development and technologies of RNA therapeutics.
    Vuong HL; Lan CT; Le HTT
    Prog Mol Biol Transl Sci; 2024; 203():13-39. PubMed ID: 38359995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA therapeutics: RNAi and antisense mechanisms and clinical applications.
    Chery J
    Postdoc J; 2016 Jul; 4(7):35-50. PubMed ID: 27570789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease.
    Schellinger IN; Dannert AR; Mattern K; Raaz U; Tsao PS
    Front Cardiovasc Med; 2021; 8():571076. PubMed ID: 33937351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
    Yu AM; Choi YH; Tu MJ
    Pharmacol Rev; 2020 Oct; 72(4):862-898. PubMed ID: 32929000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into RNA-based Therapies for Ovarian Cancer.
    Keyvani V; Mahmoudian RA; Mollazadeh S; Kheradmand N; Ghorbani E; Khazaei M; Saeed Al-Hayawi I; Hassanian SM; Ferns GA; Avan A; Anvari K
    Curr Pharm Des; 2023; 29(34):2692-2701. PubMed ID: 37916491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-coding RNAs: Therapeutic Strategies and Delivery Systems.
    Ling H
    Adv Exp Med Biol; 2016; 937():229-37. PubMed ID: 27573903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of nucleic acid therapeutics for cancer immunotherapy.
    Zhou S; Chen W; Cole J; Zhu G
    Med Drug Discov; 2020 Jun; 6():. PubMed ID: 34337382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies.
    Adachi H; Hengesbach M; Yu YT; Morais P
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34068948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Limitless Future of RNA Therapeutics.
    Damase TR; Sukhovershin R; Boada C; Taraballi F; Pettigrew RI; Cooke JP
    Front Bioeng Biotechnol; 2021; 9():628137. PubMed ID: 33816449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.